Zai Lab (ZLAB) Asset Writedowns and Impairment (2020 - 2026)
Zai Lab's (ZLAB) quarterly Asset Writedowns and Impairment came in at -$15000.0 in Q1 2026, down 155.56% year-on-year from $27000.0 in Q1 2025, and down 100.13% quarter-over-quarter from $11.4 million in Q4 2025.
Zai Lab (ZLAB) Asset Writedowns and Impairment (2020 - 2026) Analysis & Trends
Zai Lab has disclosed Asset Writedowns and Impairment across 7 years of filings, most recently posting -$15000.0 for Q1 2026.
- Asset Writedowns and Impairment for Q1 2026 came in at -$15000.0, down 155.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.2 million (up 1356.12% YoY), and the FY2025 annual result was $12.3 million, up 1407.73% from the prior year.
- Asset Writedowns and Impairment came in at -$15000.0 for Q1 2026 at Zai Lab, down from $11.4 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $11.4 million in Q4 2025 to a low of -$759000.0 in Q3 2024.
- The 5-year median for Asset Writedowns and Impairment is $2500.0 (2022), against an average of $821562.5.
- Across the five-year window, Asset Writedowns and Impairment plunged 23066.67% in 2023 and soared 37650.0% in 2024, its largest moves.
- Zai Lab's Asset Writedowns and Impairment stood at $3000.0 in 2022, then slumped by 23066.67% to -$689000.0 in 2023, then soared by 218.72% to $818000.0 in 2024, then soared by 1289.85% to $11.4 million in 2025, then sank by 100.13% to -$15000.0 in 2026.
- The last three Asset Writedowns and Impairment figures came in at -$15000.0 (Q1 2026), $11.4 million (Q4 2025), and $918000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Zai Lab | 20.15 Bn | 20.05 Bn | 61.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15,000.00 |
| Mar 31, 2026 | -15,000.00 |
| Dec 31, 2025 | 11.37 Mn |
| Dec 31, 2025 | 11.37 Mn |
| Sep 30, 2025 | 918,000.00 |
| Sep 30, 2025 | 918,000.00 |
| Jun 30, 2025 | -26,000.00 |
| Jun 30, 2025 | -26,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Dec 31, 2024 | 818,000.00 |
| Dec 31, 2024 | 818,000.00 |
| Sep 30, 2024 | -759,000.00 |
| Sep 30, 2024 | -759,000.00 |
| Jun 30, 2024 | 755,000.00 |
| Jun 30, 2024 | 755,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | -689,000.00 |
| Dec 31, 2023 | -689,000.00 |